A patent review of apelin receptor (APJR) modulators (2014-2019)
- 20 February 2020
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Therapeutic Patents
- Vol. 30 (4) , 251-261
Abstract
Introduction: The apelinergic system is regarded as a novel therapeutic target for cardiovascular health, fluid homeostasis, the hypothalamic-pituitary-adrenal (HPA) axis as well as carbohydrate and fat metabolism. Two endogenous peptide ligands, namely apelin and elabela, have been demonstrated to moderate its various metabolic and neurological functions. Both bind with high (sub)-nanomolar affinity to APJR but get degraded rapidly in circulation. In addition, various diseases have been associated with the depletion of these regulatory peptides. Besides blocking the degrading proteases, a common strategy in targeting drugs to APJR is the development of metabolically stable peptide analogs or small molecule modulators. Supporting this trend, patent literature has evolved from 121 patents in 2014 to a total of almost 1000 patents today. Areas covered: This review includes WIPO-listed small molecule and peptide-based agonists, antagonists and allosteric modulators of APJR published between 2014 and 2019. Expert opinion: Both apelin peptide analogues and small molecule modulators are emerging, only recently including one example of an elabela-based analogue. Patent activity is predominantly on agonistic modulators, since they show higher affinity and fewer off-target effects. Although several low nanomolar binders with half-lives exceeding 24 h have been confirmed in animal-models, clinical validation of these drug-targets is sparse.Keywords
This publication has 70 references indexed in Scilit:
- Discovery of a Competitive Apelin Receptor (APJ) AntagonistChemMedChem, 2011
- Disruption of the Apelin-APJ System Worsens Hypoxia-Induced Pulmonary HypertensionArteriosclerosis, Thrombosis, and Vascular Biology, 2011
- Acute Cardiovascular Effects of Apelin in HumansCirculation, 2010
- Identification and pharmacological properties of E339–3D6, the first nonpeptidic apelin receptor agonistThe FASEB Journal, 2009
- [Pyr 1 ]Apelin-13 Identified as the Predominant Apelin Isoform in the Human HeartHypertension, 2009
- Hydrolysis of Biological Peptides by Human Angiotensin-converting Enzyme-related CarboxypeptidaseJournal of Biological Chemistry, 2002
- Safe Use of the CXCR4 Inhibitor ALX40-4C in HumansAIDS Research and Human Retroviruses, 2001
- Structure of human neutral endopeptidase (neprilysin) complexed with phosphoramidon 1 1Edited by R. HuberJournal of Molecular Biology, 2000
- Isolation and Characterization of a Novel Endogenous Peptide Ligand for the Human APJ ReceptorBiochemical and Biophysical Research Communications, 1998
- A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11Gene, 1993